Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although benzodiazepines (BZDs) are commonly used in the treatment of posttraumatic stress disorder (PTSD), no systematic review or meta-analysis has specifically examined this treatment. The goal of this study was to analyze and summarize evidence concerning the efficacy of BZDs in treating PTSD. METHODS: The review protocol was undertaken according to the principles recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and is registered with the PROSPERO international prospective register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO, registration number CRD42014009318). Two authors independently conducted a search of all relevant articles using multiple electronic databases and independently abstracted information from studies measuring PTSD outcomes in patients using BZDs. Eighteen clinical trials and observational studies were identified, with a total of 5236 participants. Outcomes were assessed using qualitative and quantitative syntheses, including meta-analysis. RESULTS: BZDs are ineffective for PTSD treatment and prevention, and risks associated with their use tend to outweigh potential short-term benefits. In addition to adverse effects in general populations, BZDs are associated with specific problems in patients with PTSD: worse overall severity, significantly increased risk of developing PTSD with use after recent trauma, worse psychotherapy outcomes, aggression, depression, and substance use. Potential biopsychosocial explanations for these results are proposed based on studies that have investigated BZDs, PTSD, and relevant animal models. CONCLUSIONS: The results of this systematic review suggest that BZDs should be considered relatively contraindicated for patients with PTSD or recent trauma. Evidence-based treatments for PTSD should be favored over BZDs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BZD use is associated with an increased risk of substance use, depression, and aggression; increased PTSD severity; and decreased efficacy of trauma-focused psychotherapy.163”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [163]
In the citing paper
“BZD use is associated with an increased risk of substance use, depression, and aggression; increased PTSD severity; and decreased efficacy of trauma-focused psychotherapy.163”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [163]
In the citing paper
“BZD use is associated with an increased risk of substance use, depression, and aggression; increased PTSD severity; and decreased efficacy of trauma-focused psychotherapy.163”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [163]
In the citing paper
“BZD use is associated with an increased risk of substance use, depression, and aggression; increased PTSD severity; and decreased efficacy of trauma-focused psychotherapy.163”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [163]
In the citing paper
“BZD use is associated with an increased risk of substance use, depression, and aggression; increased PTSD severity; and decreased efficacy of trauma-focused psychotherapy.163”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [163]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Substance Use Disorders in Patients With Posttraumatic Stress Disorder: A Review of the Literature
Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1184 · Cited by 1,041
Posttraumatic stress disorder in general intensive care unit survivors: a systematic review
Davydow, D. S., Gifford, J. M., Desai, S. V., Needham, D. M., & Bienvenu, O. J. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2008.05.006 · Cited by 676
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.369 · Cited by 535
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 420
Prolonged exposure in patients with chronic PTSD: predictors of treatment outcome and dropout
van Minnen, A., Arntz, A., & Keijsers, G. P. J. (2002) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(01)00024-9 · Cited by 393
Jones, C., Bäckman, C., Capuzzo, M., Flaatten, H., Rylander, C., & Griffiths, R. D. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0600-8 · Cited by 392
Research works printed but not linked: 2
- Rosen, 2013, Schnurr PP, et al.., Do benzodiazepines reduce the effectiveness of exposure therapy for posttraumatic stress disorder J Clin Psychiatry, 74, 1241
- Pary, 2008, Prescribing benzodiazepines in clinical practice., Resid Staff Physician, 54, 8
Cited by
Exposure therapy for PTSD: A meta-analysis
McLean, C. P., Levy, H. C., Miller, M. L., & Tolin, D. F. (2022) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102115 · Cited by 273
Krystal, J. H., Davis, L. L., Neylan, T. C., A. Raskind, M., Schnurr, P. P., Stein, M. B., Vessicchio, J., Shiner, B., Gleason, T. D., & Huang, G. D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.007 · Cited by 265
“Furthermore, benzodiazepines, historically one of the medications most commonly prescribed in patients with PTSD, failed to show efficacy in small pilot studies (44,45) and interfered with fear extinction in another study (46); although one study with a hypnotic drug (eszopiclone) was positive (47).”
BackgroundBenzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
“To the contrary, PTSD [31,36,44,58] and phobias [59] have evidence of ineffectiveness or even harm.”
BackgroundInfluentialSelf-citationFeder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20050596 · Cited by 246
“Although benzodiazepines have not shown beneficial effects in the few studies conducted with PTSD patients (31), midazolam could have induced transient benefits in some patients, potentially raising the bar for demonstrating the efficacy of ketamine for PTSD and possibly underlying the absence of between-group differe…”
BackgroundTreatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Metadata
- Authors
- GUINA, J., ROSSETTER, S. R., DeRHODES, B. J., NAHHAS, R. W., & WELTON, R. S.
- Affiliations
- Wright State University (US)
- Venue
- Journal of Psychiatric Practice
- Published
- 2015-07
- Volume
- 21
- Issue
- 4
- Pages
- 281-303
- ISSN
- 1527-4160 (ISSN-L)
- 1538-1145
- OpenAlex
- W2286167367
- Cited by
- 341
- References
- 44
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 44 · 2023: 34 · 2022: 66 · 2021: 34 · 2020: 36 · 2019: 29 · 2018: 21 · 2017: 21 · 2016: 18 · 2015: 1
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychiatric Practice (publishedVersion)
- PubMed (publishedVersion)
- CORE Scholar (Wright State University) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Social Sciences › Psychology › Clinical Psychology › Migration, Health and Trauma
- Keywords
- benzodiazepines, post-traumatic stress disorder, benzodiazepine adverse effects, PTSD prevention, aggression, depression, substance use, psychotherapy outcome, biopsychosocial mechanisms, animal models
- MeSH terms
- Animals, Benzodiazepines, Clinical Trials as Topic, Depression, Humans, Psychiatric Status Rating Scales, Stress Disorders, Post-Traumatic, Treatment Outcome, Risk Assessment, Substance-Related Disorders, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1097/pra.0000000000000091
- The paper
- GUINA, J., ROSSETTER, S. R., DeRHODES, B. J., NAHHAS, R. W., & WELTON, R. S. (2015). Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. Journal of Psychiatric Practice. https://doi.org/10.1097/pra.0000000000000091
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.